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ABSTRACT Although the TEM-1 -lactamase (BlaTEM-1) hydrolyzes penicillins and
narrow-spectrum cephalosporins, organisms expressing this enzyme are typically sus-
ceptible to -lactam/-lactamase inhibitor combinations such as piperacillin-
tazobactam (TZP). However, our previous work led to the discovery of 28 clinical iso-
lates of Escherichia coli resistant to TZP that contained only blaTEM-1. One of these
isolates, E. coli 907355, was investigated further in this study. E. coli 907355 exhib-
ited significantly higher -lactamase activity and BlaTEM-1 protein levels when grown
in the presence of subinhibitory concentrations of TZP. A corresponding TZP-
dependent increase in blaTEM-1 copy number was also observed, with as many as
113 copies of the gene detected per cell. These results suggest that TZP treatment
promotes an increase in blaTEM-1 gene dosage, allowing BlaTEM-1 to reach high
enough levels to overcome inactivation by the available tazobactam in the culture.
To better understand the nature of the blaTEM-1 copy number proliferation, whole-
genome sequence (WGS) analysis was performed on E. coli 907355 in the absence
and presence of TZP. The WGS data revealed that the blaTEM-1 gene is located in a
10-kb genomic resistance module (GRM) that contains multiple resistance genes and
mobile genetic elements. The GRM was found to be tandemly repeated at least 5
times within a p1ESCUM/p1ECUMN-like plasmid when bacteria were grown in the
presence of TZP.
IMPORTANCE Understanding how bacteria acquire resistance to antibiotics is es-
sential for treating infected patients effectively, as well as preventing the spread of
resistant organisms. In this study, a clinical isolate of E. coli was identified that dedi-
cated more than 15% of its genome toward tandem amplification of a ~10-kb resis-
tance module, allowing it to escape antibiotic-mediated killing. Our research is sig-
nificant in that it provides one possible explanation for clinical isolates that exhibit
discordant behavior when tested for antibiotic resistance by different phenotypic
methods. Our research also shows that GRM amplification is difficult to detect by
short-read WGS technologies. Analysis of raw long-read sequence data was required
to confirm GRM amplification as a mechanism of antibiotic resistance.
KEYWORDS Escherichia coli, TEM-1, antibiotic resistance, gene amplification,
piperacillin-tazobactam
-Lactam antibiotics are an important class of antimicrobial agents that include peni-
cillins, narrow- and extended-spectrum cephalosporins, monobactams, and carbapen-
ems. They act by inhibiting cell wall synthesis and promoting cell lysis upon osmotic
shock. There are four main resistance mechanisms that allow bacteria to circumvent the
effects of -lactams: target modification of bacterial penicillin binding proteins (PBPs),
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upregulation of efflux pumps, alteration of porin expression or function, and
-lactamase enzyme production (1). The combined presence of these mechanisms in
individual strains has been documented (2).
-Lactamases are enzymes that inactivate -lactam antibiotics by hydrolyzing the
-lactam ring. More than 2,000 unique naturally occurring -lactamase enzymes have
been identified to date (3). The TEM -lactamases, a group containing more than 200
variants (http://www.lahey.org/Studies/temtable.asp), are all presumably derived from
the first identified TEM protein, TEM-1. The BlaTEM-1 enzyme hydrolyzes penicillins and
narrow-spectrum cephalosporins, placing it in functional classification group 2b (4, 5).
According to the molecular classification system, it is a class A serine -lactamase (6).
Although the blaTEM-1 gene is usually plasmid-borne, it is actively spread via transpo-
sition and its insertion into the chromosome has been documented (7–10).
To preserve and extend the utility of -lactams, some have been used in combina-
tion with -lactmase inhibitors. For example, amoxicillin, ampicillin, and piperacillin are
used in combination with the -lactamase inhibitors clavulanate, sulbactam, and
tazobactam, respectively. These classical inhibitors render most organisms that express
class A serine -lactamases susceptible to -lactams, excluding a few enzymes that are
inhibitor resistant, such as Klebsiella pneumoniae carbapenemases (KPCs) (1). However,
intensive use of -lactamase inhibitors has caused the emergence of inhibitor-resistant
variants within the TEM and SHV -lactamase families. In addition, overexpression of
inhibitor-sensitive enzymes, such as BlaTEM-1, has led to clavulanate, sulbactam, and/or
tazobactam resistance (11–20). In some cases, higher BlaTEM-1 enzyme levels were
attributed to a Pa/Pbmutation in the blaTEM-1 promoter that increased transcription (12,
17, 18, 21). BlaTEM-1 hyperproduction resulting from an increase in blaTEM-1 gene dosage
has also been documented (12, 13, 15, 22, 23).
We have identified a number of clinical E. coli isolates that exhibit discordant
behavior and heterogeneous resistance in disk diffusion (DD), agar dilution (AD), and
broth microdilution (BMD) antibiotic susceptibility testing (AST) assays (24, 25). A PCR-
and sequence-based screen for plasmid-borne -lactamase genes revealed that many
of the isolates harbored only blaTEM-1. In this study, we further characterized one of
these clinical isolates, combining phenotypic and genotypic approaches to characterize
a unique mechanism of antibiotic resistance.
RESULTS
Previous work revealed that E. coli clinical isolate 907355 is resistant to piperacillin-
tazobactam (TZP; MIC for the combination, 128 g/ml piperacillin and 4 g/ml
tazobactam [expressed here as 128/4 g/ml]) in BMD tests, yet susceptible (MIC,
16/4 g/ml) by the AD method (24, 25). To further investigate the nature of this
discordant behavior, BMD assays were performed with two other -lactam/-lactamase
inhibitor combinations, ampicillin-sulbactam (SAM) and amoxicillin-clavulanate (AMC).
According to Clinical and Laboratory Standards Institute (CLSI) breakpoints (26), E. coli
907355 is resistant to both SAM (MIC, 64/32 g/ml) and AMC (MIC, 32/16 g/ml) by
BMD (Table 1). Thus, the mechanism underlying E. coli 907355 resistance to TZP likely
extends to other -lactam/-lactamase inhibitor combinations.
We next examined whether increasing the concentration of tazobactam within the
TZP formulation renders 907355 susceptible to piperacillin in BMD assays. E. coli 907355
exhibited a TZP MIC of 128 g/ml when the tazobactam concentration was between
0 and 8 g/ml, whereas 16 to 64 g/ml tazobactam reduced the 907355 TZP MIC to
2 g/ml (Fig. 1A). As a control, a BMD assay was performed with 128 g/ml
tazobactam alone, which did not affect 907355 growth (data not shown). Therefore, the
decrease in the 907355 TZP MIC at higher tazobactam concentrations was not due to
tazobactam toxicity. The experiment was also performed on E. coli ATCC 35218, a CLSI
quality control (QC) organism that expresses BlaTEM-1 and is resistant to piperacillin yet
susceptible to TZP. The MICs for ATCC 35218 were 2 g/ml at all tazobactam
concentrations tested (Fig. 1B), revealing that 907355 requires a much higher concen-
tration of tazobactam than ATCC 35218 for TZP to be effective.
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We previously performed PCR assays on E. coli 907355 to detect multiple plasmid-
borne -lactamase genes. The product from the only positive reaction was sequenced,
revealing that E. coli 907355 contains blaTEM-1 (24). At the deduced amino acid
sequence level, E. coli 907355 BlaTEM-1 is 100% identical to the original BlaTEM-1.
Therefore, 907355 resistance to TZP, SAM, and AMC is not due to acquisition of inhibitor
resistance mutations within the blaTEM-1 gene. Further analysis of 907355 by isoelectric
focusing (IEF) confirmed that the isolate expresses only the BlaTEM-1 -lactamase, which
has a pI of 5.4 (Table 1). In addition, the 907355 blaTEM-1 gene has a wild-type P3
promoter (35 to 1) region (Table 1). In a previous study, the P3 promoter directed
relatively low levels of blaTEM expression compared to the Pa/Pb, P4, and P5 promoters
(21). Therefore, sequence variations in the RNA polymerase binding site are likely not
the primary cause of -lactam–-lactamase inhibitor resistance in E. coli 907355.
TABLE 1 Summary of phenotypic and genotypic characteristics of E. coli 907355
Genotype or phenotype examined Result
SAMa MIC (g/ml) 64/32
AMCa MIC (g/ml) 32/16
-Lactamase pIb 5.4
blaTEM-1 promoter P3
OmpF expressionc Yes
OmpC expressionc Yes
Increased efflux (PAN)d No
aMICs for SAM (ampicillin-sulbactam) and AMC (amoxicillin-clavulanic acid) were determined in broth
microdilution assays.
b-Lactamase pI was determined by IEF.
cOmpF and OmpC expression was detected by Western immunoblotting.
dIncreased efflux was measured in an PAN inhibitor assay. A 4-fold decrease in the TZP MIC in the
presence of 50 M PAN was considered significant.
FIG 1 Effect of increasing tazobactam concentrations on E. coli susceptibility to TZP. MICs were
determined for 907355 (A) and ATCC 35218 (B) via BMD in the presence of piperacillin (PIP) alone or TZP
formulations containing different fixed concentrations (2 to 64 g/ml) of tazobactam (TAZ). The MIC
values in the legend are based on the concentration of piperacillin in the TZP formulation that inhibited
growth. The range of MIC values obtained from six experiments is represented within each stacked bar
on the graphs.
TZP Resistance Due to blaTEM-1 Amplification
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To better understand why E. coli 907355 is resistant to TZP, BlaTEM-1 levels were
determined by Western immunoblotting following growth in liquid media containing
no antibiotic, tazobactam (4 g/ml), piperacillin (4 g/ml), or TZP (4/4 g/ml). A
subinhibitory concentration of TZP was utilized, as 907355 does not consistently grow
in liquid cultures at higher TZP concentrations despite the fact that it is resistant to TZP
in BMD assays. E. coli ATCC 25922 was included as a negative control, as this strain lacks
the blaTEM-1 gene. As expected, BlaTEM-1 was not detected in the ATCC 25922 protein
sample (Fig. 2A). In contrast, a protein with the estimated molecular mass of BlaTEM-1
(31.5 kDa) was detectable in the positive-control strain ATCC 35218 grown in the
presence of no antibiotic, tazobactam, or piperacillin.
The Western immunoblotting results showed that E. coli 907355 BlaTEM-1 levels
varied in response to the antibiotic treatment. In the presence of tazobactam alone,
BlaTEM-1 levels were lower than under the other growth conditions (Fig. 2A). Quantita-
tion of the 907355 BlaTEM-1 band intensities in each lane, which were normalized to
total protein levels (data not shown), revealed that tazobactam reduced BlaTEM-1 levels
by approximately 2.7-fold below those for cells grown without supplementation. This
phenomenon was not specific to 907355 BlaTEM-1, as it also occurred in ATCC 35218
(Fig. 2A). One possible explanation for this finding is that tazobactam binding desta-
bilizes BlaTEM-1, leading to increased degradation of the protein. Alternatively, BlaTEM-1
levels may be equal in untreated and tazobactam-treated cells, but tazobactam may
partially block the primary antibody binding site during the immunoblotting proce-
dure. We did not investigate this observation further, as the primary goal of this study
was to determine the mechanism of BlaTEM-1-mediated TZP resistance in E. coli 907355.
The Western immunoblotting also revealed that E. coli BlaTEM-1 levels are signifi-
cantly higher in the presence of TZP in comparison to no antibiotic, tazobactam, or
piperacillin (Fig. 2A). Quantitation of the BlaTEM-1 band intensities indicated that
BlaTEM-1 levels were 3.7-fold higher in the presence of TZP versus no antibiotic and
9.9-fold higher in the presence of TZP than with tazobactam alone. Thus, TZP selection
considerably increased BlaTEM-1 protein levels in E. coli 907355.
To confirm that TZP elevates the amount of BlaTEM-1 in E. coli 907355, we measured
-lactamase enzyme activity via a nitrocefin hydrolysis assay after growth in the
presence or absence of 4/4 g/ml TZP. E. coli 907355 BlaTEM-1 activity was approxi-
mately 2.2-fold higher than that of ATCC 35218 BlaTEM-1 in the absence of antibiotic
FIG 2 Effects of TZP on E. coli 907355 BlaTEM-1 levels and -lactamase enzyme activity. (A) Detection of
BlaTEM-1 in E. coli ATCC 25922 (lane 2), ATCC 35218 (lanes 3 to 5), and 907355 (lanes 6 to 9) by Western
immunoblotting. Strains were cultured in medium containing no antibiotic (lanes 2, 3, and 6), 4 g/ml
tazobactam (lanes 4 and 7), 4 g/ml piperacillin (lanes 5 and 8), or 4/4 g/ml TZP (lane 9) prior to protein
sample collection. Molecular mass standards are shown in lane 1 (kilodaltons are indicated to the left of
the blot). The estimated molecular mass of BlaTEM-1 is 31.5 kDa. This experiment was repeated on
independently collected samples and yielded similar results. (B) Determination of BlaTEM-1 activity in
E. coli 907355 via a nitrocefin hydrolysis assay after growth in the presence or absence of 4/4 g/ml TZP.
ATCC 35218 BlaTEM-1 activity is included as a comparison but was not determined (ND) in the presence
of TZP due to lack of growth. Units on the y axis denote the micromoles of nitrocefin hydrolyzed per
milligram of total protein per minute. The values above each bar on the graph represent the means of
3 experiments, and the error bars indicate the standard deviations of the means.
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(Fig. 2B). In addition, 907355 BlaTEM-1 activity increased by ~3.5-fold in the presence of
TZP in comparison to no antibiotic (Fig. 2B). As controls, the experiment was also
performed on E. coli 907355 grown in 4 g/ml piperacillin or tazobactam alone.
Piperacillin did not significantly affect BlaTEM-1 activity in comparison to no additive,
whereas tazobactam inhibited -lactamase activity, as expected (data not shown).
These results are consistent with the finding that TZP increases E. coli 907355 BlaTEM-1
production.
Based on previous studies, we suspected that the TZP-induced increase in 907355
BlaTEM-1 activity might be due to an increase in blaTEM-1 gene dosage (13, 15, 22, 23).
The copy numbers per cell for E. coli 907355 and ATCC 35218 blaTEM-1 genes were
determined using a SYBR green quantitative PCR (qPCR) assay after bacterial growth in
cation-adjusted Mueller-Hinton broth (CAMHB) containing or lacking subinhibitory
concentrations of TZP (4/4 g/ml). As a reference for cell number, qPCR was also
performed on the dxs gene, which is present in single copy on the E. coli chromosome.
The concentration of each blaTEM-1 product was divided by the concentration of dxs in
the same sample to determine the relative number of copies of blaTEM-1 per cell.
The blaTEM-1 gene was found to be present at an average copy number of only 2.3
per cell in ATCC 35218 (Fig. 3). In contrast, the 907355 blaTEM-1 gene copy number per
cell rose from 8.4 in the absence of TZP to 33.8 in the presence of TZP. These results
suggest that 4/4 g/ml TZP induces a ~4-fold increase in blaTEM-1 gene dosage, which
is responsible for the elevated BlaTEM-1 activity. As controls, piperacillin and tazobactam
were tested individually for effects on blaTEM-1 gene copy number. Neither piperacillin
nor tazobactam alone influenced blaTEM-1 gene dosage (data not shown), indicating
that the increase in copy number per cell is due to treatment with a combination of
antibiotic and inhibitor.
To further investigate the mechanism of blaTEM-1 copy number proliferation and
genomic changes in E. coli 907355, bacteria grown in absence or presence of TZP were
sequenced using Illumina technology. After assembly and annotation of the WGS data,
the contig containing blaTEM-1 was only ~ 2 kb. Therefore, the same samples were
sequenced again using the PacBio and MinION platforms, which allow longer raw
sequence reads. A draft hybrid assembly constructed from the Illumina and PacBio data,
available under BioProject PRJNA431448 on the NCBI website (https://www.ncbi.nlm
.nih.gov), revealed that the genome is approximately 5.38 Mb. The blaTEM-1 gene resides
within an approximately 10-kb region, similar to the genomic resistance module (GRM)
found in the chromosome of E. coli UMN026 (Fig. 4) (10). Unlike the chromosomal GRM
in E. coli UMN026, the 907355 GRM is located on a large plasmid similar to p1ESCUM
(additionally called p1ECUMN), which was also first identified in UMN026 (10, 27).
FIG 3 Estimation of blaTEM-1 copy number by qPCR. blaTEM-1 copy number per cell was measured using
a real-time SYBR green qPCR assay after bacterial growth in the absence or presence of 4/4 g/ml TZP.
The copy number was not determined (ND) for ATCC 35218 in the presence of TZP due to lack of growth.
The values above each bar on the graph represent the mean results of 3 experiments, and the error bars
indicate the standard deviations of the means.
TZP Resistance Due to blaTEM-1 Amplification
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MinION sequence data further illuminated the genomic structure and location of the
GRM. Examination of these reads confirmed that the GRM in 907355 p1ESCUM inter-
rupts traI, which encodes a DNA helicase/relaxase normally required for plasmid
conjugative transfer (28).
Previous studies in E. coli have attributed -lactam/-lactamase inhibitor or broad-
spectrum cephalosporin resistance to the localization of blaTEM-1 on high-copy-number
plasmids (15, 22, 23). To determine whether the observed increase in E. coli 907355
blaTEM-1 gene dosage is due to p1ESCUM accumulation, we analyzed raw Illumina and
PacBio WGS data and calculated approximate copy numbers for blaTEM-1, ebr, and three
tra genes (traI, traJ, and traK) averaged together (Table 2). Copy numbers were
estimated by dividing the sequence coverage for each p1ESCUM gene by the mean
coverage for seven single-copy E. coli multilocus sequence type (MLST) genes (adk,
fumC, gyrB, icd, mdh, purA, and recA). Independent calculations from the Illumina and
PacBio WGS data indicated that blaTEM-1 copy number increased ~4- to 5-fold in the
presence of 4/4 g/ml TZP (Table 2), similar to the results obtained with qPCR (Fig. 3).
Raising the TZP concentration to 8/8 g/ml further augmented the blaTEM-1 copy
number to more than 90 per cell (Table 2). Similarly, the estimated copy number for ebr,
another gene on the GRM (Fig. 4), increased 4- to 5-fold upon exposure to 4/4 g/ml
TZP and reached 89 copies or more per cell in 8/8 g/ml TZP (Table 2). In contrast, the
average copy number for the three tra genes, which are not on the GRM, was ~1 in the
absence of antibiotic selection and remained stable upon exposure to TZP (Table 2).
Thus, the increase in E. coli 907355 blaTEM-1 copy number in response to TZP is not
simply due to accumulation of the entire p1ESCUM plasmid.
Based on the copy number analysis of p1ESCUM genes, we hypothesized that the
~10-kb GRM is amplified within the plasmid as a result of TZP selection. In support of
this theory, five PacBio reads were identified that contained one full GRM and two
partial GRMs on either side (suggesting up to three adjacent GRMs) when 907355 was
grown in 8/8 g/ml TZP. Furthermore, one MinION read was identified that contained
three full adjacent GRMs with two partial GRMs on either side (suggesting up to five
adjacent GRMs). In both cases, the number of repeats detected was limited by the read
lengths provided by the sequencing platform. Reads containing the GRM bordered on
both sides by the interrupted traI gene were not observed (data not shown). These
findings suggest that at higher TZP levels, we were unable to detect the entire
amplified region and that the 907355 p1ESCUM plasmid likely contains more than five
tandem copies of the GRM.
In some bacteria, inactivation of major porin genes plays a role in blaTEM-1-mediated
-lactam/-lactamase inhibitor or cephalosporin resistance (29–32). To determine
whether E. coli 907355 major porin genes are intact, we identified homologues of the
E. coli K-12 MG1655 ompF and ompC genes within the 907355 assembled WGS data by
FIG 4 Resistance island containing blaTEM-1 gene in E. coli 907355. Annotation is based upon the E. coli UMN026 complete genome sequence (10, 27). Genes
are shaded according to function: gray, transposon elements and integrase; blue, pseudogenes; orange, antibiotic resistance; green, heavy metal or toxic
compound efflux; purple, hypothetical protein.
TABLE 2 Estimation of blaTEM-1 copy number based on two WGS technologies
NGS technology TZP concn (g/ml)
Mean sequence coveragea Estimated gene copy no.
MLST genes blaTEM-1 gene tra genes ebr gene blaTEM-1 gene tra genes ebr gene
Illumina None 52.3 554.8 53.0 556.1 10.6 1.0 10.6
4/4 62.3 3,358.0 94.5 3,218.8 53.9 1.5 51.7
8/8 30.5 3,450.0 38.9 2,995.7 113.3 1.3 98.3
PacBio None 113.9 1,363.5 104.2 1,094.0 12.0 0.9 9.6
4/4 163.4 7,537.5 264.7 6,825.8 46.1 1.6 41.8
8/8 83.2 7,523.3 160.5 7,410.4 90.4 1.9 89.1
aSee text for calculation method.
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using the NCBI BLAST program (https://blast.ncbi.nlm.nih.gov/Blast.cgi). The E. coli
907355 ompF and ompC genes are predicted to encode full-length proteins that are
99% and 95% identical to their respective homologues in E. coli K-12 MG1655. In
addition, the levels of OmpF and OmpC were examined in E. coli 907355 and ATCC
35218 by Western immunoblotting after bacterial growth in CAMHB, the medium used
for BMD assays. OmpF expression was barely detectable in both strains, likely due to the
relatively high osmolarity of the medium. However, a protein with the predicted
molecular mass of OmpF was apparent in both 907355 and ATCC 35218 upon over-
exposure of the blot (see Fig. S1 in the supplemental material). OmpC, which is highly
expressed in CAMHB, was also present at similar levels in 907355 and ATCC 35218 (data
not shown). These results show that reduction of OmpF and OmpC expression does not
account for 907355 TZP resistance in BMD assays.
Increased antibiotic efflux might also influence -lactam/-lactamase inhibitor re-
sistance in 907355. To examine this possibility, we utilized Phe–Arg–-naphthylamide
(PAN), a known efflux inhibitor (33, 34). The presence of 50 M PAN did not reduce
the 907355 TZP MIC in a BMD assay, suggesting that increased efflux may not play a
significant role in 907355 TZP resistance (Table 1).
DISCUSSION
In this study, the mechanism of -lactam/-lactamase inhibitor resistance was
investigated in E. coli 907355, a clinical isolate containing the blaTEM-1 gene. Experi-
mental and genomic data support a role for blaTEM-1 gene amplification, leading to
BlaTEM-1 hyperproduction, as the primary basis for -lactam/-lactamase inhibitor
resistance in this isolate. Notably, we found that blaTEM-1 is located within a ~10-kb
region that includes other resistance genes, as well as transposon- and integron-related
sequences. Others have termed this element a genomic resistance module, or GRM (10).
In the absence of antibiotic selection, our qPCR and WGS raw read data suggest that
the 907355 GRM is present at ~8 to 12 copies per cell (Fig. 3; Table 2). In the presence
of 8/8 g/ml TZP, the GRM copy number per cell increased approximately 10-fold to
90. These results translate to at least an ~800-kb increase in 907355 genomic DNA
during TZP treatment and dedication of more than 15% of the E. coli 907355 bacterial
genome to antibiotic resistance. Because 907355 TZP resistance is heterogeneous (25),
our estimation of GRM levels is likely an average of the various copy numbers present
within the population. Therefore, GRM amplification may actually be higher than
10-fold within a proportion of the population.
Multiple examples in the literature document the contributions of tandem gene
duplication and amplification to the development of antibiotic resistance (35–38). In
fact, two studies have reported that BlaTEM-1 hyperproduction may result from tandem
amplification of the blaTEM-1 gene. In one report, Sun et al. engineered a laboratory
strain of Salmonella enterica serovar Typhimurium to carry the blaTEM-1 gene on an F=
plasmid, and then they exposed it to increasing levels of cephalothin or cefaclor by
serial passage (32). Several clones with higher MICs contained large regions (36 to
134 kb) of tandemly amplified DNA that included the blaTEM-1 gene. In another study
on a clinical isolate of E. coli, genetic rearrangements and an increase in blaTEM-1 copy
number were observed within a single large, low-copy-number plasmid (13). However,
the nature of the amplification was not precisely determined. Thus, our work is
significant in that it provides direct evidence for tandem gene amplification of blaTEM-1
in a clinical isolate.
Our findings lend support to multiple aspects of the model proposed by Sandegren
and Andersson, which details a stepwise process for the contribution of gene amplifi-
cation to the development of antibiotic resistance (35). In the first step, gene duplica-
tion and amplification provide initial increased tolerance against an antibiotic (35).
Accordingly, our data show that amplification of blaTEM-1 increases E. coli 907355
tolerance to TZP. Second, tandemly amplified regions are usually genetically unstable
and lost in the absence of selection. This theory is supported by the fact that E. coli
907355 blaTEM-1 copy number and BlaTEM-1 levels were much lower when cultures were
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grown without TZP (Fig. 2 and 3). Third, mutations within the amplified genes or other
single-copy genes may allow cells to develop more durable resistance that does not
require tandem gene amplification. In fact, several studies have identified decreased
membrane permeability as a contributor to -lactam/-lactamase inhibitor or cepha-
losporin resistance in bacteria containing blaTEM-1 (29–32). Our initial examination of
E. coli 907355 membrane permeability revealed that OmpF and OmpC are expressed
(see Fig. S1 in the supplemental material) and that PAN did not significantly reduce
the TZP MIC. These results may explain why E. coli 907355 amplifies blaTEM-1 to such
high levels in the presence of TZP. However, it is important to note that E. coli 907355
membrane permeability was not extensively characterized and the isolate may have a
deficiency that we did not detect.
In addition to supporting a role for tandem blaTEM-1 amplification in the develop-
ment of -lactam/-lactamase inhibitor resistance, our work underscores two impor-
tant implications for clinical microbiology laboratories. First, our data may explain why
E. coli isolates that contain only blaTEM-1 frequently exhibit discordant or heterogeneous
behavior when tested by different AST methods for TZP (24, 25). Because the BMD
reference method uses a fixed concentration of 4 g/ml of tazobactam, which binds
irreversibly to -lactamase enzymes, a threshold level of blaTEM-1 may overcome the
available inhibitor. E. coli 907355 may be resistant to TZP in BMD assays, because a cell
that amplifies blaTEM-1 to high enough levels outgrows other cells with fewer copies of
blaTEM-1. In contrast, 907355 may be susceptible to TZP when tested via agar-based
methods because cells that express high enough BlaTEM-1 levels appear as isolated
colonies. Accordingly, increasing the concentration of tazobactam overcame 907355
resistance to TZP in BMD assays (Fig. 1). A similar observation was described previously
for other BlaTEM-1 hyperproducing strains (39). Taken together, our findings suggest
that the in vitro resistance of 907355 may represent an artifact of the BMD testing
system, which uses a fixed concentration of tazobactam in combination with increasing
concentrations of piperacillin. TZP resistance in this case may not translate into
clinical resistance of the organism in a patient therapeutic setting, where higher
concentrations of tazobactam could be obtained. In support of this theory, neu-
tropenic mice infected with bacteria identified as TZP resistant by BMD, but
susceptible to other classes of -lactams, were successfully treated with humanized
exposures of TZP (40, 41).
A second important clinical implication of our work is that blaTEM-1 gene amplifica-
tion is difficult to detect by current genotypic antibiotic susceptibility prediction
methods. First, clinical isolates are typically subcultured on media without antibiotic
selection prior to carrying out both genotypic and phenotypic assays. Because tan-
demly amplified regions are inherently unstable, they may be lost prior to testing.
Second, blaTEM-1 amplification in E. coli 907355 was not detectable by Illumina sequenc-
ing alone, as this method generates short sequencing reads (151 bp) that are not easily
assembled in repetitive regions of the genome. Similarly, a recent study employing
Illumina sequencing to generate WGS data was unable to accurately predict TZP
susceptibility in 13 of the isolates tested (42). Combining Illumina data with longer
PacBio reads, which were an average length of ~1.7 kb in our study, allowed a more
complete assembly of the E. coli 907355 blaTEM-1 region. In addition, MinION technology
was useful because it produced even longer reads than PacBio, allowing us to detect
at least five adjacent copies of the GRM within the genome of the culture treated with
8/8 g/ml TZP. Finally, classical PCR detection assays for blaTEM only reveal that the
gene is present and not whether it is tandemly amplified. Comparison of blaTEM regions
in a variety of clinical isolates resistant to TZP may reveal common sequences that can
be utilized for development of PCR assays that detect tandem gene amplification.
Our finding that a clinical isolate of E. coli significantly amplifies blaTEM-1 in response
to TZP raises important questions. For example, how commonly are isolates similar to
E. coli 907355 found in clinical settings? Although we cannot answer this question
definitively, a preliminary screening of nine other E. coli isolates from our previously
published studies revealed that at least four other independent clinical isolates have
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the ability to substantially amplify blaTEM-1 (data not shown). We are currently working
on characterizing these isolates. Further studies will be required to determine the
frequency of similar strains in natural populations.
Another question is whether blaTEM-1 gene amplification occurs in infected patients
during therapy with -lactam antibiotics or -lactam/-lactamase inhibitor combina-
tions. Unfortunately, the antibiotic treatment regimen of the patient from which E. coli
907355 was isolated was not available to us. Furthermore, E. coli 907355 isolates were
not collected prior to and over the course of the antibiotic therapy. Future studies in
mice might address whether blaTEM-1 amplification occurs in E. coli 907355 during host
infection (40, 41). Recently, McGann et al. reported that aph1 amplification occurred in
Acinetobacter baumanii during tobramycin treatment of an infected patient, leading to
antibiotic therapy failure (36). Clinical studies will be required to determine whether
extensive blaTEM-1 amplification contributes to antibiotic therapy failure for -lactam
antibiotics or -lactam/-lactamase inhibitor combinations.
MATERIALS AND METHODS
Bacterial isolates. E. coli 907355, a clinical isolate received from Austria, has been described
previously (24, 25). E. coli ATCC 25922 (blaTEM-1 negative) and/or ATCC 35218 (blaTEM-1 positive) quality
control organisms recommended by CLSI for AST were used as comparators in experiments. Although
ATCC 35218 produces BlaTEM-1, it is susceptible to -lactam/inhibitor combinations, including TZP.
AST. MICs were determined by BMD according to CLSI standard methods, using CAMHB supple-
mented with appropriate ranges of -lactam antibiotics (26, 43). -Lactamase inhibitors were included
at the recommended fixed concentrations, except that the concentration of tazobactam varied between
2 and 64 g/ml for the experiment in Fig. 1 (26). Resistance or susceptibility was interpreted using CLSI
breakpoints (26). When skipped wells were encountered during reading of the MIC, CLSI recommenda-
tions were followed for interpretation.
Bacterial growth and sample collection. For all BlaTEM-1 protein characterization assays and blaTEM-1
qPCR studies, bacteria were cultured in CAMHB with no antibiotic, 4 g/ml tazobactam, 4 g/ml
piperacillin, and/or 4/4 g/ml TZP. Cultures were inoculated with a 1:300 dilution of a 0.5 McFarland
suspension and incubated overnight at 35°C without agitation. After 18 to 20 h, cells were harvested by
centrifugation. For Western immunoblotting, equal amounts of cells (~1.5 ml of each culture) were
pelleted based on readings of the optical density at 600 nm. Pellets were then suspended in 100 l 2
Laemmli sample buffer (Bio-Rad) and frozen at 20°C. For enzyme activity and PCR experiments, pellets
(from 1-ml culture aliquots) were suspended in 0.1 M sodium phosphate buffer, pH 7.0.
For WGS analysis, E. coli 907355 bacteria were cultured overnight on Mueller-Hinton agar (MHA)
plates supplemented with 4/4 g/ml, 8/8 g/ml, or no TZP. Approximately 10 isolated colonies were
then inoculated into CAMHB containing the same concentrations of antibiotics as the MHA plates.
Cultures were grown overnight at 35°C with agitation and pelleted by centrifugation. Pellets were stored
at 20°C prior to DNA isolation.
Isoelectric focusing and Western immunoblotting. IEF was performed using pH 3 to 10 precast IEF
protein gels (Novex) and the XCell SureLock Mini-Cell (Life Technologies, Inc.) per the manufacturer’s
instructions. -Lactamase proteins were detected with 1 mM nitrocefin (Remel), using known enzymes
as standards.
For Western immunoblotting, samples were boiled for 5 min and loaded (12 l) onto a Mini-Protean
TGX Stain-Free gel (Bio-Rad). Precision Plus protein standards (Bio-Rad) were run simultaneously to
estimate molecular weight. Following separation by electrophoresis in a Protean Tetra cell (Bio-Rad),
proteins were transferred onto a polyvinylidene difluoride membrane by using the Trans-Blot Turbo
system (Bio-Rad). BlaTEM-1 was detected using a standard Western immunoblotting procedure with the
Clarity Western ECL substrate (Bio-Rad), as instructed by the manufacturer. Primary anti--lactamase
8A5.A10 mouse monoclonal antibodies (Santa Cruz Biotechnology) were used at a 1:200 dilution, and
secondary goat anti-mouse IgG–horseradish peroxidase conjugate antibodies (Bio-Rad) were used at a
13,000 dilution. Blots were developed on a ChemiDoc MP imager with Image Lab v5.2 software
(Bio-Rad). Total protein on the blot was visualized using the Stain-Free protocol, whereas chemilumi-
nescent signals were captured using the Chemi-Hi resolution protocol. Relative levels of BlaTEM-1 in E. coli
907355 samples were calculated by the Image Lab software, which quantitated the intensities of the
chemiluminescent BlaTEM-1 bands and normalized them to total protein.
-Lactamase enzyme activity assays. Lysates for -lactamase enzyme studies were prepared using
glass beads as previously described (44). Briefly, cell suspensions in phosphate buffer were transferred to
microcentrifuge tubes containing about 0.25 g of 100-m glass beads. The tubes were vortexed at full
speed with a bead beater attachment at 4°C for 10 min and then centrifuged at 16,000  g at 4°C for
15 min. Supernatants were transferred to clean tubes and stored at 20°C until testing. -Lactamase
activity assays were carried out in triplicate in an Infinite M200 Pro microplate reader (Tecan) at 25°C
using 100 M nitrocefin and 5 l of each crude glass bead lysate, as previously described (11, 45).
Enzyme rates were normalized to the total protein present in each lysate, which was determined with a
bicinchoninic acid assay kit (Thermo Scientific) per the manufacturer’s instructions.
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Determination of blaTEM-1 copy number by PCR. Lysates for blaTEM-1 gene copy number analysis
were prepared by boiling bacterial suspensions for 10 min, followed by storage at 20°C prior to testing
(46). Real-time qPCR was performed in a LightCycler 1.5 system (Roche) with SYBR green I (Roche) and
primers that hybridize to the target gene blaTEM-1 or the single-copy chromosomal reference gene, dxs
(D-1-deoxyxylulose 5-phosphate synthase), using a method similar to that reported by Lee et. al. (47).
However, the reverse primer for dxs was moved downstream 1 nucleotide, based on mismatches
detected for other E. coli dxs sequences in GenBank. Native Taq DNA polymerase isolated from Thermus
aquaticus (Invitrogen/Thermo Fisher Scientific) was utilized in all reaction mixtures due to the possible
contamination of recombinant Taq preparations with blaTEM-1 DNA. Absolute quantification analysis was
performed using LightCycler software v3.5.3 with the automated method. An internal calibrator of 1.5 
105 copies of pBR322/l spiked into 1.5  105 CFU/l of DH5 was included in each run to control for
PCR efficiency and was used to normalize the target and reference results from each sample. To
determine the concentrations of blaTEM-1 or dxs in each sample, normalized crossing point (Cp) values
were compared to a standard curve generated by performing qPCR on known quantities of each target.
The dxs standard curve was generated by performing qPCR on DH5 lysates made from samples with a
range of established CFU per microliter (4.7  103 CFU/l up to 6  105 CFU/l). The blaTEM-1 standard
curve was generated by qPCR on samples containing a range of pBR322 DNA concentrations (1.3  103
plasmids/l up to 1.0  108 plasmids/l) spiked into DH5. The number of double-stranded copies per
microliter of blaTEM-1 was then divided by the number of double-stranded copies of dxs per microliter to
determine the relative number of copies of blaTEM-1 per cell.
Bacterial genome sequencing and data interpretation. E. coli 907355 genomic DNA was isolated
from cultures containing 0, 4/4 g/ml, or 8/8 g/ml TZP by using the DNeasy blood and tissue kit
(Qiagen) according to the manufacturer’s instructions. A whole-genome shotgun library was then
constructed from each sample by using a TruSeq Nano DNA High-Throughput Library Prep kit (Illumina)
according to Illumina’s standardized protocol. Dual indexed paired-end libraries with an average insert
size of 800 bp were made by shearing 200 ng genomic DNA with a Q800R sonicator system (QSonica)
in a total volume of 50 l 1 Tris-EDTA buffer. The sheared DNA was cleaned and size selected using
sample purification beads provided in the library preparation kit. Universal adapters for paired-end
sequencing and indexing were then added according to an optimized protocol from Illumina. The
indexed libraries were pooled and sequenced on a HiSeq 2500 system (Illumina) with a target of 100
coverage per genome.
PacBio sequencing libraries were prepared using an SMRTbell Template Prep kit 1.0 (Pacific Biosci-
ences) according to the manufacturer’s standard protocol. Genomic DNA was extracted using an
extraction kit (Qiagen) and 1 g of DNA was used as the template to prepare SMRTbell libraries. DNA was
sheared using a Covaris g-TUBEs apparatus at 4,000 rpm for 3 to 4 min and cleaned using 0.75 AMPure
XP beads (Beckman Coulter, Inc.) to size select the desired range of fragments and remove all DNA
fragments of 200 bp. SMRTbell-adapted libraries were sequenced on one SMRT cell, using P6C4v2
chemistry. Output files were processed and assembled into CCS reads by using PacBio RSII SMRT portal
software (v2.3.0) default settings with minimum passes at three and minimum predicted accuracy of 0.9.
MinION sequencing libraries were prepared from unsheared genomic DNA using the SQK-MAP005
2D library preparation kit (Oxford Nanopore Technologies) and the EXP-LWI001 low-input expansion kit
(Oxford Nanopore Technologies) when less than 1 g of DNA was available. To ensure minimal shearing
during the library preparation process, the general procedure provided by Oxford Nanopore Technolo-
gies was adapted to use of wide-bore pipette tips, as well as a HulaMixer (Thermo Fisher Scientific) in
place of vortexing. Libraries were sequenced using R7.3 chemistry, and poretools was used to extract
fastq files from the native HDF5 format (48).
A hybrid de novo assembly of PacBio and Illumina reads was generated using SPAdes 3.9 with the
“multiple-kmer” and “careful” options (49). All assembled contigs were annotated using the automated
annotation software Prokka v1.11 (50). A BLAST search against NCBI GenBank identified the closest
homologous E. coli completed genome, and then a subsequent BLAST against this completed genome
was performed to manually refine annotation of the blaTEM-1-containing element (51).
Determination of gene copy number by analysis of WGS data. Copy numbers of individual genes
were determined by calculating ratios of the coverage of the gene of interest to the mean coverage of
seven E. coli MLST genes (http://mlst.warwick.ac.uk/mlst/dbs/Ecoli). These MLST genes are involved in
housekeeping functions and are known to be present in single copy within the genome. The copy
number analysis was performed separately for the Illumina and PacBio sequencing data. To estimate the
copy number of the p1ESCUM-like plasmid, the copy number of the traI, traJ, and traK genes was
averaged and compared to the mean MLST gene copy number. Read mapping and coverage estimation
were performed by using BWA v0.77 and SAMtools v0.1.19 (52, 53).
Efflux inhibitor assay. An assay using PAN (Sigma-Aldrich) was performed as previously described,
except TZP was used (54). A 4-fold decrease in TZP MIC in the presence of PAN was considered a
significant decrease.
Outer membrane protein detection. Samples for outer membrane protein detection were prepared
by diluting a 2.0 McFarland suspension 1:200 in 5 ml CAHMB. Cultures were grown to mid-log phase
(~2.5 to 3.0 McFarland), and equal volumes of cells based on McFarland readings (~1 ml) were pelleted
in a microcentrifuge. The pellets were then suspended in 100 l 2 Laemmli sample buffer and frozen
at 20°C.
Outer membrane proteins were detected according to the Western immunoblotting procedure
described above, except using different antibodies. Primary antibodies, either anti-OmpF or anti-OmpC
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polyclonal IgG (Biorbyt), were used at a 11,000 dilution. Secondary goat anti-rabbit IgG–horseradish
peroxidase conjugate antibodies (Bio-Rad) were used at a 13,000 dilution.
Accession number(s). All sequence and assembly data are accessible through NCBI BioProject
PRJNA431448.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/mBio
.00583-18.
FIG S1, DOC file, 0.1 MB.
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